Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBE50 plus aspirin vs aspirin in cerebral small vessel disease
ChiCTR2600122600Phase 4Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Ginkgo biloba extract 50 in Cerebral Small Vessel Disease (CSVD) and lacunar infarct (2 arms), sponsored by Renji Hospital. Primary endpoints: Neurofilament light chain (NfL) level and Glial fibrillary acidic protein (GFAP) level. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Ginkgo biloba extract 50
03
Conditions
Cerebral Small Vessel Disease (CSVD)lacunar infarct
Beyond the preview
Go deeper on ChiCTR2600122600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122600.